↓ Skip to main content

Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium

Overview of attention for article published in BMC Urology, March 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium
Published in
BMC Urology, March 2012
DOI 10.1186/1471-2490-12-8
Pubmed ID
Authors

Maria E Goossens, Frank Buntinx, Steven Joniau, Koen Ackaert, Filip Ameye, Ignace Billiet, Johan Braeckman, Alex Breugelmans, Jochen Darras, Kurt Dilen, Lieven Goeman, Eliane Kellen, Bertrand Tombal, Siska Van Bruwaene, Ben Van Cleyenbreuge, Frank Van der Aa, Kris Vekemans, Hendrik Van Poppel, Maurice P Zeegers

Abstract

In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported that selenium concentrations were inversely associated with the risk of bladder cancer. This suggests that selenium may also be suitable for chemoprevention of recurrence.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 42 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 16%
Student > Bachelor 7 16%
Professor 5 12%
Researcher 4 9%
Student > Ph. D. Student 4 9%
Other 8 19%
Unknown 8 19%
Readers by discipline Count As %
Medicine and Dentistry 17 40%
Biochemistry, Genetics and Molecular Biology 4 9%
Neuroscience 3 7%
Nursing and Health Professions 3 7%
Agricultural and Biological Sciences 3 7%
Other 3 7%
Unknown 10 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2012.
All research outputs
#7,785,392
of 12,410,450 outputs
Outputs from BMC Urology
#164
of 306 outputs
Outputs of similar age
#64,148
of 117,019 outputs
Outputs of similar age from BMC Urology
#3
of 4 outputs
Altmetric has tracked 12,410,450 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 306 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 117,019 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.